572 related articles for article (PubMed ID: 20574659)
41. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
[TBL] [Abstract][Full Text] [Related]
42. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
43. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
44. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma.
Iagaru AH; Mittra ES; McDougall IR; Quon A; Gambhir SS
Nucl Med Commun; 2008 Dec; 29(12):1046-51. PubMed ID: 18987524
[TBL] [Abstract][Full Text] [Related]
45. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
46. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT.
Schmidt S; Meuli RA; Achtari C; Prior JO
Clin Nucl Med; 2015 May; 40(5):371-7. PubMed ID: 25783507
[TBL] [Abstract][Full Text] [Related]
47. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
48. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence.
El-Bawab HY; Abouzied MM; Rafay MA; Hajjar WM; Saleh WM; Alkattan KM
Interact Cardiovasc Thorac Surg; 2010 Oct; 11(4):395-9. PubMed ID: 20639307
[TBL] [Abstract][Full Text] [Related]
49. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
51. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.
Mangili G; Picchio M; Sironi S; Viganò R; Rabaiotti E; Bornaghi D; Bettinardi V; Crivellaro C; Messa C; Fazio F
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):658-666. PubMed ID: 17180659
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
53. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
54. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
[TBL] [Abstract][Full Text] [Related]
55. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac.
Díaz-Montes TP; Jacene HA; Wahl RL; Bristow RE
Gynecol Oncol; 2005 Sep; 98(3):510-2. PubMed ID: 15992914
[TBL] [Abstract][Full Text] [Related]
56. The performance of contrast-enhanced FDG PET/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer.
Lee JW; Lee JH; Cho A; Yun M; Lee JD; Kim YT; Kang WJ
Clin Nucl Med; 2015 Feb; 40(2):97-102. PubMed ID: 25546187
[TBL] [Abstract][Full Text] [Related]
57.
García-Talavera P; Alejo E; Arias P; Verdú A; Tamayo P; Gómez-Caminero F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):207-213. PubMed ID: 34218882
[TBL] [Abstract][Full Text] [Related]
58. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M
Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137
[TBL] [Abstract][Full Text] [Related]
59. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
[TBL] [Abstract][Full Text] [Related]
60. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]